Carrie R McDonald1,2, Anders M Dale3,4,1,2, Pranay Kothari5, Nathan S White3,1, Nikdokht Farid3,1, Romy Chung3, Joshua M Kuperman3,1, Holly M Girard1, Ajit Shankaranarayanan6, Santosh Kesari4,7. 1. Multimodal Imaging Laboratory, University of California, San Diego, La Jolla, CA. 2. Department of Psychiatry, University of California, San Diego, La Jolla, CA. 3. Department of Radiology, University of California, San Diego, La Jolla, CA. 4. Department of Neurosciences, University of California, San Diego, La Jolla, CA. 5. School of Medicine, University of California, San Diego, La Jolla, CA. 6. GE Healthcare. 7. Translational Neuro-Oncology Laboratories, Moores Cancer Center, UC San Diego, La Jolla, CA, 92093.
Abstract
BACKGROUND AND PURPOSE: Antiangiogenic therapies, such as bevacizumab, decrease contrast enhancement and FLAIR hyperintensity in patients with high-grade gliomas in a manner that may not correlate with actual tumor response. This study evaluated the ability of an advanced DWI technique, restriction spectrum imaging, to improve conspicuity within regions of restricted diffusion compared with ADC in patients treated with bevacizumab and to demonstrate that unlike ADC, restriction spectrum imaging is less affected by bevacizumab-induced reductions in FLAIR hyperintensity. MATERIALS AND METHODS: Restriction spectrum imaging cellularity maps and DWI were available for 12 patients with recurrent high-grade gliomas at baseline and following initiation of bevacizumab. VOIs were drawn for regions of restricted diffusion, surrounding FLAIR hyperintensity, and normal-appearing white matter; and intensity values within regions of restricted diffusion and FLAIR hyperintensity were normalized to normal-appearing white matter. Normalized values were compared between restriction spectrum imaging cellularity maps and ADC at baseline and on treatment by using repeated-measures ANOVA. RESULTS: All patients exhibited decreases in contrast enhancement and FLAIR hyperintensity following treatment. Normalized intensity values were higher on restriction spectrum imaging cellularity maps compared with ADC in regions of restricted diffusion, whereas intensity values were higher on ADC compared with restriction spectrum imaging cellularity maps in regions of FLAIR hyperintensity. Bevacizumab-induced decreases in FLAIR hyperintensity had a greater effect on ADC than on the restriction spectrum imaging cellularity maps, with the relative sensitivity of ADC to changes in FLAIR hyperintensity being >20 times higher than that on restriction spectrum imaging cellularity maps. CONCLUSIONS: Restriction spectrum imaging is less influenced by reductions in FLAIR hyperintensity compared with ADC, which may confer an advantage of restriction spectrum imaging over ADC for interpreting tumor response on imaging following antiangiogenic therapy.
BACKGROUND AND PURPOSE: Antiangiogenic therapies, such as bevacizumab, decrease contrast enhancement and FLAIR hyperintensity in patients with high-grade gliomas in a manner that may not correlate with actual tumor response. This study evaluated the ability of an advanced DWI technique, restriction spectrum imaging, to improve conspicuity within regions of restricted diffusion compared with ADC in patients treated with bevacizumab and to demonstrate that unlike ADC, restriction spectrum imaging is less affected by bevacizumab-induced reductions in FLAIR hyperintensity. MATERIALS AND METHODS: Restriction spectrum imaging cellularity maps and DWI were available for 12 patients with recurrent high-grade gliomas at baseline and following initiation of bevacizumab. VOIs were drawn for regions of restricted diffusion, surrounding FLAIR hyperintensity, and normal-appearing white matter; and intensity values within regions of restricted diffusion and FLAIR hyperintensity were normalized to normal-appearing white matter. Normalized values were compared between restriction spectrum imaging cellularity maps and ADC at baseline and on treatment by using repeated-measures ANOVA. RESULTS: All patients exhibited decreases in contrast enhancement and FLAIR hyperintensity following treatment. Normalized intensity values were higher on restriction spectrum imaging cellularity maps compared with ADC in regions of restricted diffusion, whereas intensity values were higher on ADC compared with restriction spectrum imaging cellularity maps in regions of FLAIR hyperintensity. Bevacizumab-induced decreases in FLAIR hyperintensity had a greater effect on ADC than on the restriction spectrum imaging cellularity maps, with the relative sensitivity of ADC to changes in FLAIR hyperintensity being >20 times higher than that on restriction spectrum imaging cellularity maps. CONCLUSIONS: Restriction spectrum imaging is less influenced by reductions in FLAIR hyperintensity compared with ADC, which may confer an advantage of restriction spectrum imaging over ADC for interpreting tumor response on imaging following antiangiogenic therapy.
Authors: S Mong; B M Ellingson; P L Nghiemphu; H J Kim; L Mirsadraei; A Lai; W Yong; T M Zaw; T F Cloughesy; W B Pope Journal: AJNR Am J Neuroradiol Date: 2012-04-26 Impact factor: 3.825
Authors: L C Hygino da Cruz; I Rodriguez; R C Domingues; E L Gasparetto; A G Sorensen Journal: AJNR Am J Neuroradiol Date: 2011-03-10 Impact factor: 3.825
Authors: C R McDonald; N S White; N Farid; G Lai; J M Kuperman; H Bartsch; D J Hagler; S Kesari; B S Carter; C C Chen; A M Dale Journal: AJNR Am J Neuroradiol Date: 2012-12-28 Impact factor: 3.825
Authors: Nathan S White; Trygve B Leergaard; Helen D'Arceuil; Jan G Bjaalie; Anders M Dale Journal: Hum Brain Mapp Date: 2012-01-16 Impact factor: 5.038
Authors: A Gregory Sorensen; Kyrre E Emblem; Pavlina Polaskova; Dominique Jennings; Heisoog Kim; Marek Ancukiewicz; Meiyun Wang; Patrick Y Wen; Percy Ivy; Tracy T Batchelor; Rakesh K Jain Journal: Cancer Res Date: 2011-11-29 Impact factor: 12.701
Authors: C R McDonald; D J Hagler; H M Girard; C Pung; M E Ahmadi; D Holland; R H Patel; D Barba; E S Tecoma; V J Iragui; E Halgren; A M Dale Journal: Neurology Date: 2010-09-29 Impact factor: 9.910
Authors: Olivier Keunen; Mikael Johansson; Anaïs Oudin; Morgane Sanzey; Siti A Abdul Rahim; Fred Fack; Frits Thorsen; Torfinn Taxt; Michal Bartos; Radovan Jirik; Hrvoje Miletic; Jian Wang; Daniel Stieber; Linda Stuhr; Ingrid Moen; Cecilie Brekke Rygh; Rolf Bjerkvig; Simone P Niclou Journal: Proc Natl Acad Sci U S A Date: 2011-02-14 Impact factor: 11.205
Authors: T L Chenevert; L D Stegman; J M Taylor; P L Robertson; H S Greenberg; A Rehemtulla; B D Ross Journal: J Natl Cancer Inst Date: 2000-12-20 Impact factor: 13.506
Authors: Kevin C McCammack; Natalie M Schenker-Ahmed; Nathan S White; Shaun R Best; Robert M Marks; Jared Heimbigner; Christopher J Kane; J Kellogg Parsons; Joshua M Kuperman; Hauke Bartsch; Rahul S Desikan; Rebecca A Rakow-Penner; Michael A Liss; Daniel J A Margolis; Steven S Raman; Ahmed Shabaik; Anders M Dale; David S Karow Journal: Abdom Radiol (NY) Date: 2016-05
Authors: N Bahrami; D Piccioni; R Karunamuni; Y-H Chang; N White; R Delfanti; T M Seibert; J A Hattangadi-Gluth; A Dale; N Farid; C R McDonald Journal: AJNR Am J Neuroradiol Date: 2018-04-05 Impact factor: 3.825
Authors: Carrie R McDonald; Rachel L Delfanti; Anitha P Krishnan; Kelly M Leyden; Jona A Hattangadi-Gluth; Tyler M Seibert; Roshan Karunamuni; Pia Elbe; Joshua M Kuperman; Hauke Bartsch; David E Piccioni; Nathan S White; Anders M Dale; Nikdokht Farid Journal: Neuro Oncol Date: 2016-04-21 Impact factor: 12.300
Authors: K C McCammack; C J Kane; J K Parsons; N S White; N M Schenker-Ahmed; J M Kuperman; H Bartsch; R S Desikan; R A Rakow-Penner; D Adams; M A Liss; R F Mattrey; W G Bradley; D J A Margolis; S S Raman; A Shabaik; A M Dale; D S Karow Journal: Prostate Cancer Prostatic Dis Date: 2016-01-12 Impact factor: 5.554
Authors: Ahmed Boujelben; Michael Watson; Steven McDougall; Yi-Fen Yen; Elizabeth R Gerstner; Ciprian Catana; Thomas Deisboeck; Tracy T Batchelor; David Boas; Bruce Rosen; Jayashree Kalpathy-Cramer; Mark A J Chaplain Journal: Interface Focus Date: 2016-10-06 Impact factor: 3.906
Authors: Jayashree Kalpathy-Cramer; Elizabeth R Gerstner; Kyrre E Emblem; Ovidiu Andronesi; Bruce Rosen Journal: Cancer Res Date: 2014-09-01 Impact factor: 12.701
Authors: Nathan S White; Carrie McDonald; Carrie R McDonald; Niky Farid; Josh Kuperman; David Karow; Natalie M Schenker-Ahmed; Hauke Bartsch; Rebecca Rakow-Penner; Dominic Holland; Ahmed Shabaik; Atle Bjørnerud; Tuva Hope; Jona Hattangadi-Gluth; Michael Liss; J Kellogg Parsons; Clark C Chen; Steve Raman; Daniel Margolis; Robert E Reiter; Leonard Marks; Santosh Kesari; Arno J Mundt; Christopher J Kane; Christopher J Kaine; Bob S Carter; William G Bradley; Anders M Dale Journal: Cancer Res Date: 2014-09-01 Impact factor: 12.701